Pirfenidone-loaded Liposomes for Lung Targeting: Preparation and in Vitro/in Vivo Evaluation

Overview

Journal Drug Des Devel Ther

Specialty Pharmacology

Date 2015 Jul 18

PMID 26185416

Citations 8

Authors

Hui Meng

Yong Xu

Affiliations

Soon will be listed here.

Abstract

Background: The purpose of this study was to develop novel pirfenidone (PFD)-loaded liposomes for targeting to the lung.

Methods: The liposomes were prepared by the film hydration method, and their in vitro/vivo characteristics were evaluated.

Results: The PFD liposomes appeared visually as green to yellowish suspensions and were spherical in shape. The particle size was 582.3±21.6 nm and the entrapment efficiency was relatively high (87.2%±5.7%). The liposomes showed typical sustained and prolonged drug-release behavior in vitro and fitted well with the Weibull distribution equation. The relatively slower time taken to reach a minimal plasma PFD concentration in vivo suggests that PFD liposomes have a sustained-release profile, which is consistent with the results of the in vitro release study. The PFD liposomes showed the largest area under the curve for the lung. The high distribution of PFD achieved in the lungs using this liposomal formulation may be explained by physical entrapment of the liposomes in the vascular network of the lung. Histopathological results indicated that liposomal PFD could alleviate pathological injury in lung tissue.

Conclusion: This liposomal formulation can enable sustained release of PFD and increase targeting to the lung.

Citing Articles

Emerging delivery approaches for targeted pulmonary fibrosis treatment.

Diwan R, Bhatt H, Beaven E, Nurunnabi M Adv Drug Deliv Rev. 2023; 204:115147.

PMID: 38065244 PMC: 10787600. DOI: 10.1016/j.addr.2023.115147.

Impact of Antifibrotic Treatment on Postoperative Complications in Patients with Interstitial Lung Diseases Undergoing Lung Transplantation: A Systematic Review and Meta-Analysis.

Taweesedt P, Lertjitbanjong P, Eksombatchai D, Charoenpong P, Moua T, Thongprayoon C J Clin Med. 2023; 12(2).

PMID: 36675583 PMC: 9865259. DOI: 10.3390/jcm12020655.

Local Delivery of Pirfenidone by PLA Implants Modifies Foreign Body Reaction and Prevents Fibrosis.

Fayzullin A, Churbanov S, Ignatieva N, Zakharkina O, Tokarev M, Mudryak D Biomedicines. 2021; 9(8).

PMID: 34440057 PMC: 8389617. DOI: 10.3390/biomedicines9080853.

Systematic Development and Optimization of Inhalable Pirfenidone Liposomes for Non-Small Cell Lung Cancer Treatment.

Parvathaneni V, Kulkarni N, Shukla S, Farrales P, Kunda N, Muth A Pharmaceutics. 2020; 12(3).

PMID: 32121070 PMC: 7150896. DOI: 10.3390/pharmaceutics12030206.

CXCR4-targeted liposomal mediated co-delivery of pirfenidone and AMD3100 for the treatment of TGFβ-induced HSC-T6 cells activation.

Ullah A, Wang K, Wu P, Oupicky D, Sun M Int J Nanomedicine. 2019; 14:2927-2944.

PMID: 31118614 PMC: 6501422. DOI: 10.2147/IJN.S171280.

References

Miric G, Dallemagne C, Endre Z, Margolin S, Taylor S, Brown L . Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic rats. Br J Pharmacol. 2001; 133(5):687-94. PMC: 1572838. DOI: 10.1038/sj.bjp.0704131. View

Ng H, Lu A, Lin G, Qin L, Yang Z . The potential of liposomes with carbonic anhydrase IX to deliver anticancer ingredients to cancer cells in vivo. Int J Mol Sci. 2014; 16(1):230-55. PMC: 4307245. DOI: 10.3390/ijms16010230. View

Betageri G, Dipali S . Partitioning and thermodynamics of dipyridamole in the n-octanol/buffer and liposome systems. J Pharm Pharmacol. 1993; 45(10):931-3. DOI: 10.1111/j.2042-7158.1993.tb05627.x. View

Nassar P, Almeida L, Tabak M . Binding of dipyridamole to phospholipid vesicles: a fluorescence study. Biochim Biophys Acta. 1997; 1328(2):140-50. DOI: 10.1016/s0005-2736(97)00081-3. View

Meltzer E, Noble P . Idiopathic pulmonary fibrosis. Orphanet J Rare Dis. 2008; 3:8. PMC: 2330030. DOI: 10.1186/1750-1172-3-8. View

Oku H, Shimizu T, Kawabata T, Nagira M, Hikita I, Ueyama A . Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. Eur J Pharmacol. 2008; 590(1-3):400-8. DOI: 10.1016/j.ejphar.2008.06.046. View

Zhao X, Zeng X, Li X, Wang T, Wang B . Pirfenidone inhibits carbon tetrachloride- and albumin complex-induced liver fibrosis in rodents by preventing activation of hepatic stellate cells. Clin Exp Pharmacol Physiol. 2009; 36(10):963-8. DOI: 10.1111/j.1440-1681.2009.05194.x. View

Vancheri C, Failla M, Crimi N, Raghu G . Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology. Eur Respir J. 2010; 35(3):496-504. DOI: 10.1183/09031936.00077309. View

Zhao L, Wei Y, Li W, Liu Y, Wang Y, Zhong X . Solid dispersion and effervescent techniques used to prepare docetaxel liposomes for lung-targeted delivery system: in vitro and in vivo evaluation. J Drug Target. 2010; 19(3):171-8. DOI: 10.3109/10611861003801859. View

10.

Raghu G, Collard H, Egan J, Martinez F, Behr J, Brown K . An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011; 183(6):788-824. PMC: 5450933. DOI: 10.1164/rccm.2009-040GL. View

11.

Schaefer C, Ruhrmund D, Pan L, Seiwert S, Kossen K . Antifibrotic activities of pirfenidone in animal models. Eur Respir Rev. 2011; 20(120):85-97. PMC: 9487788. DOI: 10.1183/09059180.00001111. View

12.

Carter N . Pirfenidone: in idiopathic pulmonary fibrosis. Drugs. 2011; 71(13):1721-32. DOI: 10.2165/11207710-000000000-00000. View

13.

Jain S, Patil S, Swarnakar N, Agrawal A . Oral delivery of doxorubicin using novel polyelectrolyte-stabilized liposomes (layersomes). Mol Pharm. 2012; 9(9):2626-35. DOI: 10.1021/mp300202c. View

14.

Nalysnyk L, Cid-Ruzafa J, Rotella P, Esser D . Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature. Eur Respir Rev. 2012; 21(126):355-61. PMC: 9487229. DOI: 10.1183/09059180.00002512. View

15.

Ramos-Cabrer P, Campos F . Liposomes and nanotechnology in drug development: focus on neurological targets. Int J Nanomedicine. 2013; 8:951-60. PMC: 3592553. DOI: 10.2147/IJN.S30721. View

16.

Cottin V . The role of pirfenidone in the treatment of idiopathic pulmonary fibrosis. Respir Res. 2013; 14 Suppl 1:S5. PMC: 3643400. DOI: 10.1186/1465-9921-14-S1-S5. View

17.

Gibson G, Loddenkemper R, Lundback B, Sibille Y . Respiratory health and disease in Europe: the new European Lung White Book. Eur Respir J. 2013; 42(3):559-63. DOI: 10.1183/09031936.00105513. View

18.

Gradauer K, Barthelmes J, Vonach C, Almer G, Mangge H, Teubl B . Liposomes coated with thiolated chitosan enhance oral peptide delivery to rats. J Control Release. 2013; 172(3):872-8. PMC: 3913890. DOI: 10.1016/j.jconrel.2013.10.011. View

19.

Wei Y, Zhao L . Passive lung-targeted drug delivery systems via intravenous administration. Pharm Dev Technol. 2013; 19(2):129-36. DOI: 10.3109/10837450.2012.757782. View

20.

Dong Y, Feng S . Methoxy poly(ethylene glycol)-poly(lactide) (MPEG-PLA) nanoparticles for controlled delivery of anticancer drugs. Biomaterials. 2004; 25(14):2843-9. DOI: 10.1016/j.biomaterials.2003.09.055. View